Actemra (tocilizumab) Product Information (PI) - Roche Australia
Actemra (tocilizumab) Product Information (PI) - Roche Australia
Actemra (tocilizumab) Product Information (PI) - Roche Australia
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Assessment of lipid parameters should be performed in RA, pJIA and sJIA 4 to 8 weeks<br />
following initiation of ACTEMRA therapy. RA and sJIA patients should then be<br />
managed according to local clinical guidelines for management of hyperlipidaemia. For<br />
pJIA patients assessment of lipid parameters should be performed at 3 monthly intervals<br />
during ACTEMRA treatment until it is clear the risk of development of significant<br />
changes in lipid parameters has diminished.<br />
Demyelinating Disorders<br />
Physicians should be vigilant for symptoms potentially indicative of new-onset central<br />
demyelinating disorders. The potential for central demyelination with ACTEMRA is<br />
currently unknown. Multiple sclerosis and chronic inflammatory demyelinating<br />
polyneuropathy were reported rarely in RA clinical studies.<br />
Malignancy<br />
The risk of malignancy is increased in patients with RA. Immunomodulatory medicinal<br />
products may increase the risk of malignancy.<br />
Infusion Reactions<br />
Infusion reactions have been observed during and within 24 hours of treatment with<br />
ACTEMRA (see ADVERSE EFFECTS – Infusion Reactions).<br />
Cardiovascular Risk<br />
RA patients have an increased risk for cardiovascular disorders and should have risk<br />
factors (e.g. hypertension, hyperlipidaemia) managed as part of usual standard of care<br />
(see PRECAUTIONS – Lipid Parameters). Elevations in LDL and HDL lipids have been<br />
observed, with no clinical consequences identified. No data are available concerning<br />
cardiovascular outcomes with long-term use of ACTEMRA.<br />
Combination with TNF Antagonists and/or other Biological Therapies<br />
There is no experience with the use of ACTEMRA with TNF antagonists or other<br />
biological treatments for RA. ACTEMRA is not recommended for use with other<br />
biological agents including TNF antagonists, anakinra, rituximab and abatacept.<br />
Sodium<br />
This medicinal product contains 1.17 mmol (26.55 mg) of sodium per maximum dose of<br />
1200 mg. This should be taken into consideration by patients on a controlled sodium diet.<br />
Doses below 1025 mg of ACTEMRA contain less than 1 mmol of sodium (23 mg) and<br />
can essentially be considered ‘sodium free’.<br />
<strong>Actemra</strong> ® <strong>PI</strong> 131004 19 of 37<br />
CDS 8.0